Stopping clinical trials early for futility: Retrospective analysis of several randomised clinical studies

British Journal of Cancer

Volumn 107, Issue 6, 2012, Pages 910-917

  Jitlal, M ^a   Khan, I ^a   Lee, S M ^b   Hackshaw, A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

clinical trials; conditional power; early stopping; futility analysis

Indexed keywords

ANALYTIC METHOD; ARTICLE; CALCULATION; COST CONTROL; DRUG TREATMENT FAILURE; FUTILITY ANALYSIS; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; TREATMENT OUTCOME;

CLINICAL TRIALS, PHASE II AS TOPIC; EARLY TERMINATION OF CLINICAL TRIALS; HUMANS; MEDICAL FUTILITY; NEOPLASMS; ODDS RATIO; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84865863356     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.344     Document Type: Article

References (27)

1. Barthel FM, Parmar MK, Royston P (2009) How do multi-stage, multi-arm trials compare to the traditional two-arm parallel group design-a reanalysis of 4 trials. Trials 10: 1-10
2. Baum M, Hackshaw A, Houghton J, Rutqvist, Fornander T, Nordenskjold B, Nicolucci A, Sainsbury R, ZIPP International Collaborators Group (2006) Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study. Eur J Cancer 42(7): 895-904
3. DeMets DL (2006) Futility approaches to interim monitoring by data monitoring committees. Clin Trials 3: 522-529
4. Food and Drug Administration. Guidance for clinical trial sponsors. Establishment and operation of clinical trial data monitoring committees. FDA, 2006, http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm127073.pdf
5. Freidlin B, Korn EL, Gray R (2010) A general inefficacy interim monitoring rule for randomized clinical trials. Clin Trials 7: 197-208
6. Hackshaw A, Roughton M, Forsyth S, Monson K, Reczko K, Sainsbury R, Baum M (2011) Long-term benefits of 5 years of tamoxifen: 10 year follow up of a large randomised trial in women aged at least 50 years with early breast cancer. J Clin Oncol 29(13): 1657-1663
7. Halperin M, Lan KKG, Ware JH, Johnson NJ, DeMets DL (1982) An aid to data monitoring in long-term clinical trials. Control Clin Trials 3: 311-323
8. Herson J, Buyse M, Wittes JT (2011) On Stopping a Randomized Clinical Trial for Futility. In Designs for Clinical Trials: Perspectives on Current Issues, Harrington D (ed) (Applied Bioinformatics and Biostatistics in Cancer Research) Springer: USA
9. Hughes S, Cuffe RL, Lieftucht A, Garrett Nichols W (2009) Informing the selection of futility stopping thresholds: case study from a late-phase clinical trial. Pharm Stat 8(1): 25-37
10. Lachin JM (2009) Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit. Clin Trials 6: 565-573
11. Lan KKG, DeMets DL (1983) Discrete sequential boundaries for clinical trials. Biometrika 70: 659-663
12. Lan KKG, Simon R, Halperin M (1982) Stochastically curtailed tests in long-term clinical trials. Commun Stat C1: 207-219
13. Lan KKG, Wittes J (1988) The B-value: a tool for monitoring data. Biometrics 44: 579-585
14. Lee SM, Woll PJ, Rudd R, Ferry D, O'Brien M, Middleton G, Spiro S, James L, Ali K, Jitlal M, Hackshaw A (2009a) Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 101(15): 1049-1057
15. Lee SM, Rudd R, Woll PJ, Ottensmeier C, Gilligan D, Price A, Spiro S, Gower N, Jitlal M, Hackshaw A (2009b) Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 27(31): 5248-5254
16. Lee S, Rudd R, Khan I, Upadhyay S, Lewanski CR, Falk S, Skailes G, Partridge R, Ngai Y, Boshoff C (2010) TOPICAL: Randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy. J Clin Oncol 28(15s suppl): abstr 7504
17. Northover J, Glynne-Jones R, Sebag-Montefiore D, James R, Meadows H, Wan S, Jitlal M, Ledermann J (2010) Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer 102(7): 1123-1128
18. Pocock SJ (2006) Current controversies in data monitoring for clinical trials. Clin Trials 3: 513-521
19. Proschan MA, Lan KKG, Wittes JT (2006) Statistical Monitoring of Clinical Trials: A Unified Approach. 1st edn. Springer: USA
20. Royston P, Mahesh KB, Qian W (2003) Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer. Stat Med 22: 2239-2256
21. Snapinn S, Chen MG, Jiang Q, Koutsoukos T (2006) Assessment of futility in clinical trials. Pharm Stat 5(4): 273-281
22. Spiegelhalter DJ, Freedman LS, Blackburn PR (1986) Monitoring clinical trials: Conditional or predictive power? Control Clin Trials 7(1): 8-17
23. Spiro SG, James LE, Rudd RM, Trask CW, Tobias JS, Snee M, Gilligan D, Murray PA, Ruiz de Elvira MC, O'Donnell KM, Gower NH, Harper PG, Hackshaw AK, London Lung Cancer Group (2006) Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis. J Clin Oncol 24(24): 3823-3830
24. Tobias JS, Monson K, Gupta N, Macdougall H, Glaholm J, Hutchison I, Kadalayil L, Hackshaw A, UK Head and Neck Cancer Trialists' Group (2010) Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial. Lancet Oncol 11(1): 66-74
25. UKCCCR Anal Cancer Trial Working Party (1996) Epidermoid anal cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet 348: 1049-1054
26. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J, ABC-02 Trial Investigators (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14): 1273-1281
27. Whitehead J, Matsushita T (2003) Stopping clinical trials because of treatment ineffectiveness: a comparison of a futility design with a method of stochastic curtailment. Statistics in Medicine 22(5): 677-687